FY2027 EPS Estimate for Boston Scientific Lowered by Analyst

Boston Scientific Corporation (NYSE:BSX) – Investment analysts at Erste Group Bank dropped their FY2027 earnings estimates for Boston Scientific in a research note issued to investors on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the medical equipment provider will post earnings of $3.91 per share for the year, down from their prior forecast of $3.92. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

BSX has been the subject of several other reports. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Robert W. Baird dropped their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Evercore reduced their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Barclays decreased their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $106.27.

Boston Scientific Stock Up 0.4%

Shares of BSX opened at $70.08 on Thursday. The firm has a market cap of $104.16 billion, a P/E ratio of 36.13, a price-to-earnings-growth ratio of 1.08 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific has a 52 week low of $67.56 and a 52 week high of $109.50. The firm’s 50-day simple moving average is $77.83 and its 200 day simple moving average is $91.10.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares in the last quarter. State Street Corp lifted its position in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Synergy Asset Management LLC boosted its stake in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC grew its position in Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after acquiring an additional 14,700 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new position in Boston Scientific in the third quarter valued at about $26,955,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Some analysts and commentators see a potential turn in fortunes or an eventual rating upgrade if execution improves, which supports a constructive long‑term thesis for BSX. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Neutral Sentiment: Analyst model adjustments have been modest — Erste trimmed a FY2027 EPS forecast slightly — indicating analysts are tightening growth assumptions rather than making sweeping downgrades. This is a modest headwind but not a major re‑rating event by itself.
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in securities class actions alleging misstatements about U.S. electrophysiology procedure growth and related disclosures; the cases cover purchases from July 23, 2025 through Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline. This clustering increases legal and settlement risk and is weighing on the stock. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Several other firms issued investor alerts and lawsuits (Pomerantz, Portnoy, Bernstein Liebhard, Levi & Korsinsky, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Robbins Geller, etc.), reinforcing the coverage and media attention around litigation risk and potential shareholder losses. BSX Investor Alert: Securities Fraud Lawsuit (SueWallSt)
• Negative Sentiment: Market coverage of these developments coincided with recent share weakness and headlines noting sharper-than-market declines, which can amplify short‑term selling pressure as investors de‑risk exposure. Boston Scientific (BSX) Falls More Steeply Than Broader Market

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.